
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : The First Affiliated Hospital of Guangzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2016
Lead Product(s) : Urinastatin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : The First Affiliated Hospital of Guangzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2016
Lead Product(s) : Urinastatin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
Details : Kallikrein is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cerebral Infarction.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 29, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Defects, Congenital.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2015
Lead Product(s) : Urinastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin in Severe Acute Pancreatitis
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pancreatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2010
Lead Product(s) : Urinastatin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!